References
- Shalev A, Munitz H. The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatrica Scandinavica 1986; 73: 337–347
- Levenson JL. Neuroleptic malignant syndrome. American Journal of Psychiatry 1985; 142: 1137–1145
- Ebadi M, Pfeiffer R, Murrin L. Pathogenesis and treatment of neuroleptic malignant syndrome. General Pharmacology 1990; 21: 367–386
- Aisen P, Lawlor B. Neuroleptic malignant syndrome induced by low-dose haloperidol. American Journal of Psychiatry 1992; 6: 844
- Legras A, Hurel D, Dabrowski G, Grenet D, Graveleau P, Loirat P. Protracted neuroleptic malignant syndrome complicating long-acting neuroleptic administration. The American Journal of Medicine 1988; 85: 875–878
- Koponen H, Repo E, Lepola U. Long-term outcome after neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 1991; 84: 550–551
- Lee S, Merriam A, Kim T, Liebling M, Dickson D, Moore G. Cerebellar degeneration in neuroleptic malignant syndrome: Neuropathological findings and review of the literature concerning heat-related nervous system injury. Journal of Neurology, Neurosurgery, and Psychiatry 1989; 52: 387–391
- Kornhuber J. Weller M. Neuroleptic malignant syndrome. Current Opinions in Neurology 1994; 7: 353–357
- Brown T. Clozapine, neuroleptic malignant syndrome, and pancerebellar syndrome. Psychosomatics 1999; 40: 518–520
- Addonizio G, Susman V, Roth S. Neuroleptic malignant syndrome: Review of 115 cases. Biological Psychiatry 1987; 22: 1004–1020
- Lal V, Sardana V, Thussu A, Sawhney I, Prabhakar S. Cerebellar degeneration following neuroleptic malignant syndrome. Postgraduate Medical Journal 1997; 73: 735–736
- Levenson J, Fisher J. Long-term outcome after neuroleptic malignant syndrome. Journal of Clinical Psychiatry 1988; 49: 154–156
- Buckley P, Freyne A, McCarthy A, Larkin C. Neuroleptic malignant syndrome—follow-up study. Irish Journal of Medical Science 1991; 160: 45–47
- Eiser A, Neff M, Slifkin R. Acute myoglobinic failure: A consequence of the neuroleptic malignant syndrome. Archives of Internal Medicine 1982; 1452: 601–603
- Meuller P, Vester J, Fremglich J. Neuroleptic malignant syndrome: Successful treatment with bromocriptine. Journal of the American Medical Association 1983; 249: 386–388
- Kammerer T, Singer L, Patris M, Finance F, Tempe J, Rey G. Neuroleptic malignant syndrome. Ann Med Psychol 1972; 2: 550–554
- Regestein Q, Alpert J, Riech P. Sudden catatonic syndrome with disastrous outcome. Journal of the American Medical Association 1977; 238: 618–620
- Rothke S, Bush D. Neuropsychologial sequelae of neuroleptic malignant syndrome. Biological Psychiatry 1986; 21: 838–884
- Chen C, Reist C, Ko W. A follow-up of patients with neuroleptic malignant syndrome. Hospital and Community Psychiatry 1991; 42: 197–199
- Richter W, Issinger O. Differential heat shock response of primary human cell cultures and established cell lines. Biochemical and Biophysical Research Communications 1986; 141: 46–52
- Rekate H, Grubb R, Aram D, Hahn J, Ratcheson R. Muteness of cerebellar origin. Archives of Neurology 1985; 42: 697–698
- Manto M, Goldman S, Hildebrand J. Cerebellar gait ataxia following neuroleptic malignant syndrome. Journal of Neurology 1996; 243: 101–102